Trovafloxacin-Induced Acute Hepatitis
The DOI matches its Crossref record.
Abstract
Trovafloxacin, a new trifluoronaphthyridone derivative related to fluoroquinolone antimicrobial drugs, appears to be more effective than available quinolones. As a class, the most common adverse effects involve the CNS and gastrointestinal tract [1]. Liver enzyme abnormalities have been noted in 2%-3% of patients, and liver toxicity is reported infrequently [2]. Since use of this drug in the United States was authorized in December 1997, 152 cases of serious hepatic events probably related to trovafloxacin have been reported to the US Food and Drug Administration (140 cases) and to the European Agency for the Evaluation of Medicinal Products (12 cases as of July 1998). Because the frequency of serious adverse reactions to trovafloxacin was well out of proportion to that seen in other drugs in this class, the manufacturer withdrew trovafloxacin from the European markets on 15 June 1999. The drug remains available in the United States for very restricted indications [3]. We report 3 patients who had acute hepatitis after taking trovafloxacin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Chemical Aspects of Human and Environmental Overload with Fluorine
Han, J., Kiss, L., Mei, H., Remete, A. M., Ponikvar-Svet, M., Sedgwick, D. M., Roman, R., Fustero, S., Moriwaki, H., & Soloshonok, V. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01263 · Cited by 537
Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
Bush, N. G., Diez-Santos, I., Abbott, L. R., & Maxwell, A. (2020) · Molecules · doi:10.3390/molecules25235662 · Cited by 413
Drug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 405
Self-citationCunha, B. A. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70309-6 · Cited by 358
A Critical Review of the Fluoroquinolones: Focus on Respiratory Infections
Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J., Smith, H., & Hoban, D. J. (2002) · Drugs · doi:10.2165/00003495-200262010-00002 · Cited by 344
Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity
Walgren, J. L., Mitchell, M. D., & Thompson, D. C. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935620 · Cited by 322
Comparison of Two Clinical Scales for Causality Assessment in Hepatotoxicity
Lucena, M. I., Camargo, R., Andrade, R. J., Perez-Sanchez, C. J., & De La Cuesta, F. S. (2001) · Hepatology · doi:10.1053/jhep.2001.20645 · Cited by 212
Self-citationGARCÍA‐CORTÉS, M., LUCENA, M. I., PACHKORIA, K., BORRAZ, Y., HIDALGO, R., ANDRADE, R. J., & ON BEHALF OF THE SPANISH GROUP FOR THE STUDY OF DRUG‐INDUCED LIVER DISEASE (GRUPO DE ESTUDIO PARA LAS HEPATOPATÍAS ASOCIADAS A MEDICAMENTOS, G. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03655.x · Cited by 143
Self-citationSundaram, V., & Björnsson, E. S. (2017) · Hepatology Communications · doi:10.1002/hep4.1088 · Cited by 138
Shaw, P. J., Ganey, P. E., & Roth, R. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq168 · Cited by 123
Review article: drug‐induced liver injury in clinical practice
Björnsson, E. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04320.x · Cited by 108
Lucena, M. I., Kaplowitz, N., Hallal, H., Castiella, A., García-Bengoechea, M., Otazua, P., Berenguer, M., Fernandez, M. C., Planas, R., & Andrade, R. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.041 · Cited by 89
Self-citationRechallenge in drug-induced liver injury: the attractive hazard
Andrade, R. J., Robles, M., & Lucena, M. I. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903397378 · Cited by 52
Self-citationThe Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
Moreno-Torres, M., Quintás, G., & Castell, J. V. (2022) · Metabolites · doi:10.3390/metabo12060564 · Cited by 50
Iruzubieta, P., Arias-Loste, M. T., Barbier-Torres, L., Martinez-Chantar, M. L., & Crespo, J. (2015) · BioMed Research International · doi:10.1155/2015/386186 · Cited by 24
Metadata
- Authors
- Lucena, M. I., Andrade, R. J., Rodrigo, L., Salmeron, J., Alvarez, A., Lopez-Garrido, M. J., Camargo, R., & Alcantara, R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-02-01
- Volume
- 30
- Issue
- 2
- Pages
- 400-401
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2153214289
- Cited by
- 95
- References
- 0
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.